Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.
Expression of MDR1 is a well-characterized mechanism leading to resistance of tumor cells to drugs like vinca-alkaloids, anthracyclines, and epipodophyllotoxins. In hematopoiesis, recent data indicate that not only leukemic cells, but also some populations of normal hematopoietic cells, particularly CD34+ progenitor cells as well as peripheral blood lymphocytes, express a functional multidrug-resistant phenotype. Among CD34+ cells, we found evidence that myeloid committed precursor cells (CD34+/CD33+) have lower levels of MDR1 expression than earlier CD34+ cell populations, but there was no difference in MDR1 expression between CD34+/HLA-DR- and CD34+/HLA-DR+ subpopulations. During normal myeloid differentiation, MDR1 expression is down-regulated, which is similar to our observations in acute myelogenous leukemia (AML): MDR1 expression was only rarely detected in acute promyelocytic leukemia, which was in contrast to other subtypes of AML; also, within leukemic subpopulations of the same patient, higher MDR1 levels were correlated with a more immature immunophenotype. Regarding regulation of MDR1 expression, we did not observe changes of MDR1 expression in normal CD34+ cells in response to various cytokines. However, in 2 patients with AML treated with interleukin-3 and granulocyte-colony stimulating factor, respectively, a significant down-regulation of MDR1 expression was found after 24 hours. In conclusion, there is evidence that the pattern of MDR1 expression observed in leukemias reflects the distribution of MDR1 in normal hematopoiesis. In contrast to normal CD34+ cells, leukemic cells from some AML patients can respond to cytokines with a down-regulation of MDR1, which may contribute to response to cytokine/chemotherapy combinations.
Drach
J
J
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Zhao
S
S
Drach
D
D
Körbling
M
M
Engel
H
H
Andreeff
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D015703:Antigens, CD; D018952:Antigens, CD34; D001853:Bone Marrow / Q000378:metabolism*; D001854:Bone Marrow Cells; D004351:Drug Resistance / Q000235:genetics; D005786:Gene Expression Regulation; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D007938:Leukemia / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015703:Antigens, CD; D018952:Antigens, CD34; D007377:Interleukin-3; D016179:Granulocyte Colony-Stimulating Factor